Thermo Fisher Scientific introduced a new trace elemental analyzer. The Thermo Scientific iCAP RQplus ICP-MS Analyzer can be used in the pharmaceutical, food, and environmental sectors. It can be used for different sample types and trace elements at low concentrations.
The global life science instrumentation market is poised for steady growth, projected to reach USD 73.9 billion by 2028 from USD 54.9 billion in 2023, registering a CAGR of 6.1% during the forecast period (2023-2028). This growth is driven by the rising adoption of advanced analytical systems, expanding R&D investments, and the increasing prevalence of hospital-acquired infections (HAIs).
As life sciences companies pursue innovation in drug discovery, genomics, proteomics, and molecular diagnostics, the demand for precision analytical instruments and automation tools continues to accelerate. Emerging trends such as next-generation sequencing (NGS) advancements, lab digitization, and AI integration are reshaping how scientists generate, analyze, and apply biological data.
Download PDF Brochure
Market Overview: A Dynamic Shift Toward Precision and Automation
The life science instrumentation market encompasses a broad range of technologies — including spectroscopy, chromatography, sequencing, PCR, flow cytometry, and microscopy — used across biotechnology, pharmaceutical, academic, and diagnostic laboratories.
The increasing use of life science instruments in R&D is a primary growth catalyst. Pharmaceutical and biotech companies are scaling up investments to accelerate drug pipeline development, while academic and clinical researchers are adopting high-throughput, automated, and cloud-integrated instruments to streamline workflows and improve reproducibility.
Moreover, the rising burden of infectious diseases and antimicrobial resistance has heightened the demand for sterilization, contamination control, and infection prevention systems in laboratories, driving the adoption of reliable instrumentation for accurate diagnostics.
Competitive Landscape: Consolidation and Strategic Expansion
The life science instrumentation market is moderately consolidated, with a mix of global leaders and emerging innovators competing for market share.
Key players include:
* Thermo Fisher Scientific Inc. (US)
* Danaher Corporation (US)
* Agilent Technologies, Inc. (US)
* Waters Corporation (US)
* Shimadzu Corporation (Japan)
* Becton, Dickinson and Company (US)
* PerkinElmer Inc. (US)
* Bio-Rad Laboratories, Inc. (US)
* Bruker (US)
* Hitachi High-Technologies Corporation (Japan)
These industry giants leverage product innovation, strategic acquisitions, and global partnerships to strengthen their portfolios.
In 2022,
Thermo Fisher Scientific, Danaher, and Agilent Technologies collectively captured a significant share of the global market due to their broad product ecosystems, global reach, and continuous R&D investment.
Key Company Insights
Thermo Fisher Scientific Inc.
Headquartered in Massachusetts, Thermo Fisher Scientific remains a leading player offering a vast portfolio of analytical instruments, reagents, consumables, and software. The company’s Thermo Scientific iCAP ROplus ICP-MS Analyzer — launched recently — enhances trace element detection across pharmaceutical, environmental, and food applications.
Operating in over 50 countries, Thermo Fisher’s global footprint and inorganic growth strategy through acquisitions reinforce its leadership in precision instrumentation and analytical services.
Danaher Corporation
Danaher, a diversified US-based conglomerate, is recognized for its innovative analytical tools and robust R&D investment. The company’s subsidiaries — such as Cytiva, Beckman Coulter Life Sciences, and Leica Microsystems — offer end-to-end solutions for molecular diagnostics and cell analysis.
Danaher’s strategy emphasizes product innovation, customer-centric service, and digital integration, with operations spanning over 60 countries.
Agilent Technologies, Inc.
Founded in 1999 and headquartered in Delaware, Agilent Technologies serves the pharmaceutical, biotechnology, and environmental testing sectors with instruments, consumables, and services. Its subsidiaries in Australia, Canada, China, and Europe highlight its strong international presence.
Agilent continues to invest in automated lab systems and AI-driven data analytics, aligning with the global shift toward smart laboratories.
Market Drivers
* Rising R&D Investments and Trial Complexity
A significant driver for the life science instrumentation market is the increasing volume and complexity of clinical trials. As pharmaceutical pipelines expand, trials are becoming more intricate, targeting niche populations in oncology, rare diseases, and gene therapies.
These complex studies demand advanced biomarker analytics, adaptive designs, and real-world evidence integration — factors that elevate the need for sophisticated analytical instrumentation and CRO partnerships to manage large, diverse datasets efficiently.
* Advancements in NGS and Molecular Biology Tools
Continuous innovation in next-generation sequencing (NGS) platforms and PCR technologies has revolutionized genomics research. High-throughput sequencing enables researchers to decode genetic data at unprecedented speed and accuracy, fueling progress in personalized medicine, biopharmaceutical development, and disease diagnostics.
* Growing Emphasis on Infection Control and Safety
The rising prevalence of hospital-acquired infections (HAIs) has intensified focus on sterilization and contamination control in life science laboratories. According to the World Health Organization (WHO), approximately 7-10% of hospitalized patients worldwide acquire infections during care — underlining the necessity of high-quality instrumentation for microbial monitoring, sterilization, and diagnostic accuracy.
Request Sample Report
Market Opportunities
Regulatory Push for Trial Diversity and Global Outreach
Regulatory bodies such as the FDA and EMA are enforcing greater diversity and inclusion in clinical research. The FDA’s 2024 Diversity Action Plan (DAP) mandates broader participant representation, while Europe’s Clinical Trials Regulation (EU No.
536/2014) encourages wider inclusion.
This creates an opportunity for CROs and life science instrument providers to collaborate on decentralized, patient-centric trials supported by real-world data technologies. Digitally enabled instruments that facilitate remote monitoring and sample processing are well-positioned to benefit from these evolving regulatory standards.
Market Challenges
Patient Retention and Trial Continuity
While technology has accelerated data capture and analysis, patient retention in clinical trials remains a challenge. Long durations, complex visit schedules, and burdensome protocols often lead to participant dropouts, affecting study endpoints.
To address this, leading organizations such as IQVIA are deploying digital engagement platforms and decentralized trial models. For example, its Health Research Space app and Mobile Research Nursing Suite provide in-home support and monitoring, minimizing dropouts and ensuring continuous participation.
Regional Outlook
The North American market dominates global revenue due to advanced research infrastructure, strong biopharma investment, and the presence of major industry players. Meanwhile, Asia Pacific is emerging as the fastest-growing region, driven by expanding R&D capabilities in China, India, and South Korea, government funding for life sciences, and the rapid adoption of genomic technologies.
Conclusion: Enabling the Future of Precision Research
The life science instrumentation market stands at the forefront of scientific transformation — empowering researchers with data-driven insights, automation, and AI-powered analytics. As the global focus shifts toward precision medicine, clinical trial diversification, and technological integration, the market will continue to be a cornerstone of biomedical innovation and healthcare advancement.
For industry stakeholders, investing in next-gen analytical platforms, strategic collaborations, and digital infrastructure will be essential to capture emerging opportunities and sustain growth in the evolving life sciences ecosystem.
News From
MarketsandMarkets™
Category: Industry Reports & Market Analysis Profile: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, w …
This email address is being protected from spambots. You need JavaScript enabled to view it.
